Pomerantz LLP investigates Vanda Pharmaceuticals for potential securities fraud.

Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) regarding potential securities fraud or unlawful business practices. Vanda received a decision letter from the FDA concluding that the supplemental New Drug Application for HETLIOZ (tasimelteon) for jet lag disorder cannot be approved in its current form, despite positive efficacy from controlled clinical trials. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.